Ignore Copaxone: Momenta Pharmaceuticals Still a Buy

Short-term worries surrounding Teva have created a great opportunity for Momenta investors with a long-term mindset.

May 19, 2014 at 2:30PM

To say that Momenta Pharmaceuticals (NASDAQ:MNTA) has been beaten down by Mr. Market in 2014 would be an understatement. The developmental-stage biotech has lost a lot of value since the beginning of the year (although some recent good news on Teva has led to some increase).

MNTA Year to Date Price Returns Chart

MNTA Year to Date Price Returns data by YCharts

Most of the decline stems from the roller-coaster ride surrounding Momenta's ability to launch a generic version of the multiple sclerosis drug Copaxone from Teva Pharmaceuticals (NYSE:TEVA). The back-and-forth court battle has taken investors through highs (the Court of Appeals ruling that Momenta would be able to launch its generic version in the first half of 2014) and lows (appeals by Teva to block a generic launch) in the past 12 months. However, I think the haircut given to shares has been a bit overdone, especially when considering the long-term opportunities brewing in the company's biosimilar pipeline with Baxter International (NYSE:BAX). I believe Momenta is worth a solid look with or without the launch of a Copaxone generic later this year. Here's why.

What Mr. Market is overlooking
It's no secret that Wall Street squanders long-term opportunities when short-term pain or uncertainty arises -- and that's exactly what I think is happening here. The Copaxone generic, named M356, is just one of more than seven pipeline products under development. That list includes up to five biosimilars under development in collaboration with Baxter for autoimmune diseases, one biosimilar under development at Momenta (after being dropped by Baxter), one novel oncology drug candidate being evaluated as a combinational therapy in advanced metastatic pancreatic cancer, and a novel sialylation platform for intravenous immunoglobulin, or IVIG, products.

By all accounts, the future looks bright. And it's not just the fact that Momenta is pursuing multiple biosimilar products that should get investors excited. The company seeks to develop biosimilar products that are superior to anything else on the market and potentially interchangeable to innovator biologics. How?

Unlike small molecule generics, which are simpler to manufacture and almost always exact copies of the innovator drug, biologic drugs are substantially more complex. That means it's extremely difficult, if not impossible, to produce exact copies of a biologic drug without the same exact host organism (with today's technology, anyway). That's also why biosimilars are required to go through clinical trials while generic small molecules are not. Momenta wants to recreate the known structure of innovator biologics while only changing the unknown structure to manufacture potentially interchangeable biosimilars.

G

Source: Momenta Pharmaceuticals.

Removing the uncertainty from producing biosimilars would boast significant advantages for Momenta and Baxter. It would increase the probability of regulatory approval, reduce the need for clinical data at the various "checkpoint" meetings with regulatory bodies, and provide a highly effective, yet cheaper, product for patients and doctors. The innovative platform developed by Momenta to characterize complex biological structures and marry it to the manufacturing process is at the heart of all products being commercialized and sold by the company.

In addition to that significant competitive advantage, Momenta exited the first quarter of 2014 with $224 million in cash. That's enough to last roughly two years at the current cash burn rate -- and it fails to account for major milestone payments from collaborative partners. For instance, two biosimilar programs are expected to trigger a $19 million payment from Baxter in the second half of the year. That will only partially offset cash burn, but it's meaningful nonetheless.

Foolish bottom line
I believe Mr. Market's focus on short-term uncertainty has created a solid opportunity for long-term investors. Momenta has a long way to go before realizing the full potential of its innovative platform, but it continues to make progress each quarter. Launching its version of Teva's Copaxone would certainly help -- and it may be able to do so in the second half of the year, particularly given that Teva just lost another court battle to delay the drug. Regardless, the potential delay to one potential market opportunity should not punish the multiple opportunities under development. I think investors should give Momenta a hard look at its current market cap hovering below $600 million.

Invest in the next wave of health-care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion-dollar industry." And the technology behind it is poised to set off one of the most remarkable health-care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential and its ability to make life-changing medical solutions never thought possible.  To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolioCAPS pageprevious writing for The Motley Fool, or his work for SynBioBeta to keep up with developments in the synthetic biology industry.

The Motley Fool recommends Baxter International, Momenta Pharmaceuticals, and Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers